Initial results of efficacy and safety of sofosbuvir among pakistani population: A real life trial hepatitis eradication accuracy trial of sofosbuvir (HEATS)

Objective: the uridine nucleotide analogue sofosbuvir is a selective inhibitor of hepatitis c virus (hcv) ns5b polymerase approved for the treatment of chronic hcv infection with genotypes 1 4. the objective of the study was to evaluate the interim results of efficacy and safety of regimens containing sofosbuvir (zoval) among pakistani population with the rapid virologic response (rvr2/4 weeks) with hcv infections. methods: this is a multicenter open label prospective observational study. patients suffering from chronic hepatitis c infection received sofosbuvir (zoval) 400 mg plus ribavirin (with or without peg interferon) for 12/24 weeks. the interim results of this study were rapid virological response on week 4. data was analyzed using spss version 21 for descriptive statistics. results: a total of 573 patients with hcv infection were included in the study. the mean age of patients was 46.07 ± 11.41 years. out of 573 patients 535 (93.3%) were treatment naive,26 (4.5%) were relapser,7 (1.2%) were non-responders and 5 (1.0%) were partial responders. a rapid virologic response was reported in 563(98.2%) of patients with hcv infection after four weeks of treatment. the treatment was generally well tolerated. conclusion: sofosbuvir (zoval) is effective and well tolerated in combination with ribavirin in hcv infected patients. © 2017 professional medical publications. all rights reserved.